Drugs and Cosmetics Bill in the works

Drugs and Cosmetics Bill in the works
Deepak Patel New Delhi
Last Updated : Jun 23 2016 | 12:24 AM IST
The government has started drafting a new Drugs and Cosmetics Bill to regulate newer areas such as biological drugs, stem cells research, regenerative medicines, medical devices and clinical trial/investigation.

The Cabinet on Wednesday decided to withdraw Drugs and Cosmetics (Amendment) Bill, 2013, introduced in the Rajya Sabha on August 2013. The Bill had been examined by Parliament's standing committee, which had made a number of recommendations to further changes.

"The Cabinet has, keeping in view the role of the sector in managing public health, decided that it will not be appropriate to carry out further amendments in the present Act," a government statement said.

Till date, the Drugs and Cosmetics Act, 1940, provided some form of regulatory framework for ensuring the quality, safety and efficacy of medical products, including of medical devices. But the government on Wednesday admitted that newer areas such as biological drugs, stem cell research, regenerative medicines, etc, cannot be effectively regulated under the existing law.

The Union health ministry has, accordingly, undertaken an exercise at two levels - to frame separate rules under the existing Act for regulating medical devices; to bring out separate legislations for regulating sectors such as drugs, medical devices and cosmetics. "After extensive discussions with all stakeholders, the draft rules for regulating medical devices have been prepared and will be notified shortly.

Work on drafting the new legislation has also been commenced," the government's statement said. "Keeping in view the objective of Make In India, it has been decided to comprehensively review the existing law with two fold objectives viz. to facilitate the ease of doing business and substantially enhancing the quality and efficacy of our products."

India is one of the largest manufacturers of pharmaceutical products in the world. The annual production of such products is in excess of Rs 2 lakh crore. Out of this, more than 55 per cent is exported.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jun 23 2016 | 12:24 AM IST

Next Story